NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) —
Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI
Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI
Data continue to support iclaprim activity against MRSA and other drug-resistant pathogens
Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that new clinical and pre-clinical data with its investigational drug candidate iclaprim are being presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018).
Positive efficacy and safety results …
READ FULL TEXT